74 related articles for article (PubMed ID: 22001609)
41. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
42. Nutritional consequences of interspecies differences in arginine and lysine metabolism.
Ball RO; Urschel KL; Pencharz PB
J Nutr; 2007 Jun; 137(6 Suppl 2):1626S-1641S. PubMed ID: 17513439
[TBL] [Abstract][Full Text] [Related]
43. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Cancer Res; 2007 May; 67(10):4869-77. PubMed ID: 17495323
[TBL] [Abstract][Full Text] [Related]
44. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
45. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Yoon CY; Shim YJ; Kim EH; Lee JH; Won NH; Kim JH; Park IS; Yoon DK; Min BH
Int J Cancer; 2007 Feb; 120(4):897-905. PubMed ID: 17096330
[TBL] [Abstract][Full Text] [Related]
46. Pegylated arginine deiminase: a novel anticancer enzyme agent.
Feun L; Savaraj N
Expert Opin Investig Drugs; 2006 Jul; 15(7):815-22. PubMed ID: 16787144
[TBL] [Abstract][Full Text] [Related]
47. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase.
Shen LJ; Beloussow K; Shen WC
Cancer Lett; 2006 Jan; 231(1):30-5. PubMed ID: 16356828
[TBL] [Abstract][Full Text] [Related]
48. Modeling of the bacterial growth curve.
Zwietering MH; Jongenburger I; Rombouts FM; van 't Riet K
Appl Environ Microbiol; 1990 Jun; 56(6):1875-81. PubMed ID: 16348228
[TBL] [Abstract][Full Text] [Related]
49. Single step protocol to purify recombinant proteins with low endotoxin contents.
Reichelt P; Schwarz C; Donzeau M
Protein Expr Purif; 2006 Apr; 46(2):483-8. PubMed ID: 16290005
[TBL] [Abstract][Full Text] [Related]
50. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
Ascierto PA; Scala S; Castello G; Daponte A; Simeone E; Ottaiano A; Beneduce G; De Rosa V; Izzo F; Melucci MT; Ensor CM; Prestayko AW; Holtsberg FW; Bomalaski JS; Clark MA; Savaraj N; Feun LG; Logan TF
J Clin Oncol; 2005 Oct; 23(30):7660-8. PubMed ID: 16234528
[TBL] [Abstract][Full Text] [Related]
51. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
Sarkissian CN; Gámez A
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S22-6. PubMed ID: 16165390
[TBL] [Abstract][Full Text] [Related]
52. Insights into the interaction of human arginase II with substrate and manganese ions by site-directed mutagenesis and kinetic studies. Alteration of substrate specificity by replacement of Asn149 with Asp.
López V; Alarcón R; Orellana MS; Enríquez P; Uribe E; Martínez J; Carvajal N
FEBS J; 2005 Sep; 272(17):4540-8. PubMed ID: 16128822
[TBL] [Abstract][Full Text] [Related]
53. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma.
Cheng PN; Leung YC; Lo WH; Tsui SM; Lam KC
Cancer Lett; 2005 Jun; 224(1):67-80. PubMed ID: 15911102
[TBL] [Abstract][Full Text] [Related]
54. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells.
Wheatley DN
Semin Cancer Biol; 2005 Aug; 15(4):247-53. PubMed ID: 15886013
[TBL] [Abstract][Full Text] [Related]
55. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
Izzo F; Marra P; Beneduce G; Castello G; Vallone P; De Rosa V; Cremona F; Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA; Ng C; Curley SA
J Clin Oncol; 2004 May; 22(10):1815-22. PubMed ID: 15143074
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates.
Yang Z; Wang J; Yoshioka T; Li B; Lu Q; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
Clin Cancer Res; 2004 Mar; 10(6):2131-8. PubMed ID: 15041734
[TBL] [Abstract][Full Text] [Related]
57. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle.
Husson A; Brasse-Lagnel C; Fairand A; Renouf S; Lavoinne A
Eur J Biochem; 2003 May; 270(9):1887-99. PubMed ID: 12709047
[TBL] [Abstract][Full Text] [Related]
58. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
59. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.
Dillon BJ; Holtsberg FW; Ensor CM; Bomalaski JS; Clark MA
Med Sci Monit; 2002 Jul; 8(7):BR248-53. PubMed ID: 12118186
[TBL] [Abstract][Full Text] [Related]
60. Glu-256 is a main structural determinant for oligomerisation of human arginase I.
Sabio G; Mora A; Rangel MA; Quesada A; Marcos CF; Alonso JC; Soler G; Centeno F
FEBS Lett; 2001 Jul; 501(2-3):161-5. PubMed ID: 11470277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
